Pharmacology Quiz: Acetaminophen And Hepatotoxicity
20 questions · exam conditions
0:00
Acetaminophen And HepatotoxicityQuestion 1 of 20

A patient presents 48 hours after a large acetaminophen ingestion. Laboratory results show AST 9,500 U/L, ALT 8,200 U/L, INR 4.2, and a serum acetaminophen level of 15 mcg/mL. Which is the most accurate interpretation of these findings?

The low acetaminophen level indicates the initial overdose was likely not significant and another cause for liver injury should be sought.
The patient has severe hepatocellular injury, and the low acetaminophen level is expected due to drug metabolism over 48 hours.
The markedly elevated aminotransferases with a low acetaminophen level are pathognomonic for ischemic hepatitis, not drug toxicity.
The elevated INR is an artifact of the lab assay and does not reflect true hepatic synthetic dysfunction.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Acetaminophen And Hepatotoxicity

Practice Acetaminophen And Hepatotoxicity in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Acetaminophen And Hepatotoxicity, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient presents 48 hours after a large acetaminophen ingestion. Laboratory results show AST 9,500 U/L, ALT 8,200 U/L, INR 4.2, and a serum acetaminophen level of 15 mcg/mL. Which is the most accurate interpretation of these findings?

  1. The low acetaminophen level indicates the initial overdose was likely not significant and another cause for liver injury should be sought.
  2. The patient has severe hepatocellular injury, and the low acetaminophen level is expected due to drug metabolism over 48 hours. (correct answer)
  3. The markedly elevated aminotransferases with a low acetaminophen level are pathognomonic for ischemic hepatitis, not drug toxicity.
  4. The elevated INR is an artifact of the lab assay and does not reflect true hepatic synthetic dysfunction.
Explanation: This clinical picture is classic for severe acetaminophen-induced hepatotoxicity. By 48 hours post-ingestion, the parent drug has been extensively metabolized, so a low or undetectable serum level is expected and does not rule out a toxic ingestion. The extremely high aminotransferase levels (AST/ALT) and elevated INR (indicating impaired synthesis of clotting factors) are hallmark signs of severe liver damage. The other options represent common misinterpretations of the laboratory data in this context.

Question 2

A patient who is 30 weeks pregnant presents after an acute acetaminophen overdose. Her 4-hour level is in the toxic range. Which statement regarding the use of N-acetylcysteine (NAC) in this patient is most accurate?

  1. NAC is contraindicated in pregnancy (Category X) due to the high risk of fetal harm.
  2. NAC should be withheld until after delivery to protect the fetus from exposure.
  3. NAC can only be given orally during pregnancy, as the intravenous form causes uterine contractions.
  4. NAC readily crosses the placenta and should be administered, as it treats both the mother and the fetus. (correct answer)
Explanation: When you encounter acetaminophen toxicity in pregnancy, remember that this is a medical emergency where the benefits of treatment far outweigh any theoretical risks. Acetaminophen overdose can cause severe hepatotoxicity and potentially fatal outcomes for both mother and fetus if left untreated. N-acetylcysteine (NAC) is the antidote of choice and works by replenishing glutathione stores, which become depleted during acetaminophen metabolism. The key insight here is that NAC readily crosses the placenta, making it uniquely valuable in pregnancy because it simultaneously treats both maternal and fetal acetaminophen toxicity. This placental transfer is actually beneficial rather than harmful. Option A is incorrect because NAC is actually Pregnancy Category B, meaning animal studies show no fetal risk and it's considered safe in pregnancy. Option B represents a dangerous misconception—withholding treatment would likely result in maternal liver failure and fetal death, as acetaminophen toxicity progresses rapidly. Option C contains false information about route restrictions; both oral and intravenous NAC can be safely used in pregnancy, and IV NAC doesn't cause uterine contractions. The correct answer is D because NAC's ability to cross the placenta makes it the ideal treatment, protecting both patients simultaneously. Time is critical in acetaminophen overdose—delays worsen outcomes significantly. Study tip: In pregnancy pharmacology questions, always consider that treating serious maternal conditions usually benefits the fetus too. Untreated maternal illness is often more dangerous to the fetus than appropriate medication use.

Question 3

Depletion of hepatic glutathione to what approximate percentage of its normal concentration is considered the critical threshold at which the toxic NAPQI metabolite begins to bind to cellular proteins, initiating hepatocyte injury?

  1. Below 90%
  2. Below 75%
  3. Below 30% (correct answer)
  4. At 0% (complete depletion)
Explanation: The liver has a robust capacity for detoxifying NAPQI via glutathione conjugation. Hepatotoxicity does not begin until this system is overwhelmed. It is widely cited that hepatic glutathione stores must be depleted to approximately 20-30% of their baseline levels before free NAPQI accumulates and significant covalent binding to mitochondrial proteins occurs, leading to cell death. Toxicity begins well before complete (0%) depletion.

Question 4

A patient presents 1 hour after ingesting 20 grams of acetaminophen. The patient is awake and alert. In addition to preparing for N-acetylcysteine administration, which other intervention is most appropriate at this time?

  1. Administration of a single dose of activated charcoal. (correct answer)
  2. Initiation of hemodialysis to remove the parent drug.
  3. Administration of intravenous vitamin K to prevent coagulopathy.
  4. Performance of emergent gastric lavage.
Explanation: Activated charcoal is effective at adsorbing drugs within the gastrointestinal tract, thereby reducing systemic absorption. It is most effective when given within 1-2 hours of ingestion. For a large, potentially lethal overdose presenting this early, administering activated charcoal is recommended to decrease the overall drug burden, followed by administration of N-acetylcysteine. Hemodialysis (B) is reserved for rare, extreme cases. Vitamin K (C) would not be effective prophylactically. Gastric lavage (D) is no longer routinely recommended due to risks and limited efficacy.

Question 5

A healthy 70-kg adult inadvertently takes two 650 mg extended-release acetaminophen tablets every 6 hours for 2 days for knee pain. What is the total daily dose, and what is the primary concern with this dosing regimen?

  1. 2600 mg/day; this is a safe and therapeutic dose.
  2. 3900 mg/day; this is at the upper limit of the recommended dose and should be used with caution.
  3. 5200 mg/day; this supratherapeutic dose increases the risk of hepatotoxicity with continued use. (correct answer)
  4. 6500 mg/day; this is an acutely toxic dose requiring immediate medical evaluation.
Explanation: This question requires calculation and risk assessment. The patient takes two 650 mg tablets per dose, which is 1300 mg/dose. Dosing every 6 hours means there are four doses in a 24-hour period (24/6 = 4). The total daily dose is 1300 mg/dose * 4 doses/day = 5200 mg/day. This exceeds the maximum recommended daily dose for an adult (typically 3000-4000 mg), placing the patient at risk for liver damage from a chronic supratherapeutic ingestion.

Question 6

A patient with a seizure disorder maintained on long-term phenytoin therapy ingests 10 grams of acetaminophen. Compared to an individual not taking phenytoin, this patient's risk of hepatotoxicity is increased primarily because phenytoin:

  1. competes with acetaminophen for glucuronidation, increasing the amount metabolized by cytochrome P450 enzymes.
  2. induces CYP2E1 and other P450 isoenzymes, accelerating the conversion of acetaminophen to NAPQI. (correct answer)
  3. directly depletes hepatic glutathione stores, reducing the capacity to detoxify NAPQI.
  4. inhibits the renal transporters responsible for clearing acetaminophen metabolites from the body.
Explanation: Phenytoin, like carbamazepine, phenobarbital, and chronic alcohol, is a potent inducer of cytochrome P450 enzymes, including CYP2E1. Enzyme induction increases the metabolic capacity of the oxidative pathway, leading to a greater fraction of an acetaminophen dose being converted to the toxic metabolite NAPQI. This increases the risk of glutathione depletion and subsequent liver injury, even at doses that might be tolerated by a person not on an inducing agent. The other mechanisms described are less significant or incorrect.

Question 7

A patient with anorexia nervosa and a BMI of 15 kg/m² presents with right upper quadrant pain after taking 4 grams of acetaminophen daily for 3 days for a headache. This patient is at increased risk of hepatotoxicity primarily due to:

  1. impaired renal clearance of acetaminophen in a malnourished state.
  2. pre-existing depletion of hepatic glutathione stores due to poor nutritional status.
  3. induction of CYP2E1 enzymes caused by chronic fasting and ketosis.
  4. both depletion of glutathione stores and induction of CYP2E1 enzymes. (correct answer)
Explanation: Malnutrition and fasting, such as in anorexia nervosa, create a dual-risk situation for acetaminophen toxicity. Poor nutritional intake leads to depleted baseline stores of glutathione, the key molecule for detoxifying NAPQI. Simultaneously, the metabolic state of fasting can induce CYP2E1, the very enzyme that produces NAPQI. This combination severely lowers the threshold for hepatotoxicity, making even therapeutic doses potentially dangerous.

Question 8

A patient presents 48 hours after a large acetaminophen ingestion. Laboratory results show AST 9,500 U/L, ALT 8,200 U/L, INR 4.2, and a serum acetaminophen level of 15 mcg/mL. Which is the most accurate interpretation of these findings?

  1. The low acetaminophen level indicates the initial overdose was likely not significant and another cause for liver injury should be sought.
  2. The patient has severe hepatocellular injury, and the low acetaminophen level is expected due to drug metabolism over 48 hours. (correct answer)
  3. The markedly elevated aminotransferases with a low acetaminophen level are pathognomonic for ischemic hepatitis, not drug toxicity.
  4. The elevated INR is an artifact of the lab assay and does not reflect true hepatic synthetic dysfunction.
Explanation: This clinical picture is classic for severe acetaminophen-induced hepatotoxicity. By 48 hours post-ingestion, the parent drug has been extensively metabolized, so a low or undetectable serum level is expected and does not rule out a toxic ingestion. The extremely high aminotransferase levels (AST/ALT) and elevated INR (indicating impaired synthesis of clotting factors) are hallmark signs of severe liver damage. The other options represent common misinterpretations of the laboratory data in this context.

Question 9

A single acute ingestion of acetaminophen is generally considered to pose a risk of hepatotoxicity in a healthy adult if the dose exceeds:

  1. 4 grams or 75 mg/kg, whichever is less.
  2. 6 grams or 100 mg/kg, whichever is less.
  3. 7.5 grams or 150 mg/kg, whichever is less. (correct answer)
  4. 10 grams or 200 mg/kg, whichever is less.
Explanation: While there is some variability, the generally accepted threshold for a potentially toxic single acute ingestion of acetaminophen in a healthy adult is 7.5 to 10 grams, or 150 mg/kg. Doses below this are unlikely to cause significant liver injury in individuals without risk factors. The value of 4 grams (A) represents the maximum recommended daily dose, not the single toxic dose. The other values are either too low or too high for the standard threshold.

Question 10

A 60-kg patient is being treated for a severe acetaminophen overdose with a standard 21-hour intravenous N-acetylcysteine (NAC) protocol. The primary mechanism by which NAC mitigates hepatotoxicity in this patient is by:

  1. inhibiting the CYP2E1 enzyme to prevent the formation of the toxic metabolite.
  2. acting as a precursor for glutathione (GSH) synthesis and directly binding to NAPQI. (correct answer)
  3. enhancing the renal clearance of acetaminophen through forced alkaline diuresis.
  4. directly chelating acetaminophen in the serum, preventing its uptake by hepatocytes.
Explanation: N-acetylcysteine has a dual mechanism of action. Its primary role is to serve as a cysteine donor, thereby repleting hepatic stores of glutathione (GSH), which is the endogenous compound responsible for detoxifying NAPQI. Additionally, NAC can act as a GSH substitute, directly binding to and detoxifying NAPQI. NAC does not inhibit CYP2E1 (A), enhance renal clearance (C), or chelate the parent drug (D).

Question 11

A 30-year-old man took 15 tablets of an extended-release acetaminophen product (650 mg/tablet) 5 hours ago. His initial 4-hour post-ingestion acetaminophen level was 130 mcg/mL, which falls below the treatment line on the standard Rumack-Matthew nomogram. What is the most appropriate next action?

  1. Discharge the patient with instructions to return if symptoms develop, as the level is non-toxic.
  2. Administer one dose of activated charcoal and observe for 24 hours.
  3. Initiate N-acetylcysteine therapy based on the ingested dose despite the non-toxic initial level.
  4. Repeat the acetaminophen level at 8 hours post-ingestion to assess for delayed peak absorption. (correct answer)
Explanation: The Rumack-Matthew nomogram is validated only for acute, single ingestions of immediate-release acetaminophen. With extended-release formulations, drug absorption is delayed and prolonged. A single 4-hour level can be misleadingly low. The standard recommendation is to obtain a second level 4-8 hours after the first. If either level is above the nomogram line, or if enzymes are elevated, NAC should be started. Discharging the patient (A) is unsafe. Charcoal (B) is too late. Initiating NAC (C) may be premature; reassessing the level is the best next step.

Question 12

A 60-kg patient is being treated for a severe acetaminophen overdose with a standard 21-hour intravenous N-acetylcysteine (NAC) protocol. The primary mechanism by which NAC mitigates hepatotoxicity in this patient is by:

  1. inhibiting the CYP2E1 enzyme to prevent the formation of the toxic metabolite.
  2. acting as a precursor for glutathione (GSH) synthesis and directly binding to NAPQI. (correct answer)
  3. enhancing the renal clearance of acetaminophen through forced alkaline diuresis.
  4. directly chelating acetaminophen in the serum, preventing its uptake by hepatocytes.
Explanation: N-acetylcysteine has a dual mechanism of action. Its primary role is to serve as a cysteine donor, thereby repleting hepatic stores of glutathione (GSH), which is the endogenous compound responsible for detoxifying NAPQI. Additionally, NAC can act as a GSH substitute, directly binding to and detoxifying NAPQI. NAC does not inhibit CYP2E1 (A), enhance renal clearance (C), or chelate the parent drug (D).

Question 13

A patient is admitted for a confirmed severe acetaminophen overdose and is being treated with intravenous N-acetylcysteine (NAC). On day 3 of admission, her AST and ALT levels, which had peaked at >10,000 U/L, begin to trend downward. However, her INR continues to increase, and she develops asterixis. What is the most likely clinical significance of these findings?

  1. The falling aminotransferases indicate the start of hepatic recovery, and the other signs will soon follow.
  2. The patient is developing an anaphylactoid reaction to the NAC infusion, requiring discontinuation.
  3. The patient is progressing to acute liver failure, as INR and encephalopathy are better markers of prognosis than AST/ALT. (correct answer)
  4. The initial overdose was from an extended-release product, requiring an additional course of NAC.
Explanation: While AST and ALT are sensitive markers of hepatocellular injury, they do not reflect liver function. INR (a measure of synthetic function) and mental status (a sign of encephalopathy) are much better indicators of overall hepatic function and prognosis. In severe cases, aminotransferases can fall as hepatocytes die and 'wash out' their enzymes, while true liver function continues to deteriorate. This clinical picture signifies progression to acute liver failure, a poor prognostic sign.

Question 14

A healthy 70-kg adult inadvertently takes two 650 mg extended-release acetaminophen tablets every 6 hours for 2 days for knee pain. What is the total daily dose, and what is the primary concern with this dosing regimen?

  1. 2600 mg/day; this is a safe and therapeutic dose.
  2. 3900 mg/day; this is at the upper limit of the recommended dose and should be used with caution.
  3. 5200 mg/day; this supratherapeutic dose increases the risk of hepatotoxicity with continued use. (correct answer)
  4. 6500 mg/day; this is an acutely toxic dose requiring immediate medical evaluation.
Explanation: This question requires calculation and risk assessment. The patient takes two 650 mg tablets per dose, which is 1300 mg/dose. Dosing every 6 hours means there are four doses in a 24-hour period (24/6 = 4). The total daily dose is 1300 mg/dose * 4 doses/day = 5200 mg/day. This exceeds the maximum recommended daily dose for an adult (typically 3000-4000 mg), placing the patient at risk for liver damage from a chronic supratherapeutic ingestion.

Question 15

A patient with anorexia nervosa and a BMI of 15 kg/m² presents with right upper quadrant pain after taking 4 grams of acetaminophen daily for 3 days for a headache. This patient is at increased risk of hepatotoxicity primarily due to:

  1. impaired renal clearance of acetaminophen in a malnourished state.
  2. pre-existing depletion of hepatic glutathione stores due to poor nutritional status.
  3. induction of CYP2E1 enzymes caused by chronic fasting and ketosis.
  4. both depletion of glutathione stores and induction of CYP2E1 enzymes. (correct answer)
Explanation: Malnutrition and fasting, such as in anorexia nervosa, create a dual-risk situation for acetaminophen toxicity. Poor nutritional intake leads to depleted baseline stores of glutathione, the key molecule for detoxifying NAPQI. Simultaneously, the metabolic state of fasting can induce CYP2E1, the very enzyme that produces NAPQI. This combination severely lowers the threshold for hepatotoxicity, making even therapeutic doses potentially dangerous.

Question 16

What is the rationale for the Food and Drug Administration (FDA) limiting the amount of acetaminophen to 325 mg per tablet in prescription combination products (e.g., with opioids)?

  1. To minimize the risk of inadvertent cumulative overdose when patients take multiple doses for severe pain. (correct answer)
  2. To reduce the analgesic efficacy of acetaminophen, promoting the use of non-opioid alternatives.
  3. Because doses higher than 325 mg have been shown to cause acute renal failure.
  4. To prevent the development of physical dependence on acetaminophen.
Explanation: When you encounter questions about FDA regulations and drug safety, focus on the agency's primary mission: protecting public health by preventing harm from medications. The FDA's 2011 decision to limit acetaminophen in prescription combination products to 325 mg per tablet directly addresses a serious public health concern. Acetaminophen overdose is the leading cause of acute liver failure in the United States, and many cases occur unintentionally. When patients take prescription opioid-acetaminophen combinations for severe pain, they often need multiple doses throughout the day. Without realizing it, they can easily exceed the maximum daily acetaminophen limit of 4,000 mg (recently reduced to 3,000 mg by many manufacturers), especially if they're also taking other acetaminophen-containing products like over-the-counter pain relievers or cold medications. Choice A correctly identifies this cumulative overdose risk as the FDA's rationale. The lower per-tablet amount provides a safety buffer, making it harder to reach toxic levels. Choice B is incorrect because the FDA's goal wasn't to reduce acetaminophen's efficacy or promote alternatives—325 mg is still therapeutically effective, especially when combined with opioids. Choice C misidentifies the primary concern. While very high acetaminophen doses can affect kidneys, the main toxicity is hepatotoxicity (liver damage), not acute renal failure. Choice D is wrong because acetaminophen doesn't cause physical dependence—that's not a pharmacological property of this drug. Remember: FDA drug regulations typically stem from documented safety concerns, not efficacy issues. Look for the answer that addresses preventing patient harm.

Question 17

Depletion of hepatic glutathione to what approximate percentage of its normal concentration is considered the critical threshold at which the toxic NAPQI metabolite begins to bind to cellular proteins, initiating hepatocyte injury?

  1. Below 90%
  2. Below 75%
  3. Below 30% (correct answer)
  4. At 0% (complete depletion)
Explanation: The liver has a robust capacity for detoxifying NAPQI via glutathione conjugation. Hepatotoxicity does not begin until this system is overwhelmed. It is widely cited that hepatic glutathione stores must be depleted to approximately 20-30% of their baseline levels before free NAPQI accumulates and significant covalent binding to mitochondrial proteins occurs, leading to cell death. Toxicity begins well before complete (0%) depletion.

Question 18

A 55-year-old woman with chronic back pain has been taking 1000 mg of acetaminophen every 4 hours for the past 6 days. She presents with nausea, malaise, and right upper quadrant abdominal pain. Her AST is 2200 U/L. Which statement is true regarding the use of the Rumack-Matthew nomogram in her case?

  1. The nomogram is the primary tool for determining her need for N-acetylcysteine therapy.
  2. A serum acetaminophen level should be drawn and plotted based on the time of her last dose.
  3. The nomogram is not applicable because it is only validated for acute, single-point ingestions. (correct answer)
  4. The nomogram can be used if the total ingested dose over 24 hours is used as the starting point.
Explanation: The Rumack-Matthew nomogram is a tool used to predict the risk of hepatotoxicity following an acute, single ingestion of immediate-release acetaminophen. It is not validated and should not be used for chronic or staggered ingestions over a period of time. In cases of chronic supratherapeutic ingestion, the decision to treat with NAC is based on clinical signs (symptoms, elevated transaminases) and a measurable acetaminophen level, not the nomogram.

Question 19

A patient who is 30 weeks pregnant presents after an acute acetaminophen overdose. Her 4-hour level is in the toxic range. Which statement regarding the use of N-acetylcysteine (NAC) in this patient is most accurate?

  1. NAC is contraindicated in pregnancy (Category X) due to the high risk of fetal harm.
  2. NAC should be withheld until after delivery to protect the fetus from exposure.
  3. NAC can only be given orally during pregnancy, as the intravenous form causes uterine contractions.
  4. NAC readily crosses the placenta and should be administered, as it treats both the mother and the fetus. (correct answer)
Explanation: When you encounter acetaminophen toxicity in pregnancy, remember that this is a medical emergency where the benefits of treatment far outweigh any theoretical risks. Acetaminophen overdose can cause severe hepatotoxicity and potentially fatal outcomes for both mother and fetus if left untreated. N-acetylcysteine (NAC) is the antidote of choice and works by replenishing glutathione stores, which become depleted during acetaminophen metabolism. The key insight here is that NAC readily crosses the placenta, making it uniquely valuable in pregnancy because it simultaneously treats both maternal and fetal acetaminophen toxicity. This placental transfer is actually beneficial rather than harmful. Option A is incorrect because NAC is actually Pregnancy Category B, meaning animal studies show no fetal risk and it's considered safe in pregnancy. Option B represents a dangerous misconception—withholding treatment would likely result in maternal liver failure and fetal death, as acetaminophen toxicity progresses rapidly. Option C contains false information about route restrictions; both oral and intravenous NAC can be safely used in pregnancy, and IV NAC doesn't cause uterine contractions. The correct answer is D because NAC's ability to cross the placenta makes it the ideal treatment, protecting both patients simultaneously. Time is critical in acetaminophen overdose—delays worsen outcomes significantly. Study tip: In pregnancy pharmacology questions, always consider that treating serious maternal conditions usually benefits the fetus too. Untreated maternal illness is often more dangerous to the fetus than appropriate medication use.

Question 20

A patient with a seizure disorder maintained on long-term phenytoin therapy ingests 10 grams of acetaminophen. Compared to an individual not taking phenytoin, this patient's risk of hepatotoxicity is increased primarily because phenytoin:

  1. competes with acetaminophen for glucuronidation, increasing the amount metabolized by cytochrome P450 enzymes.
  2. induces CYP2E1 and other P450 isoenzymes, accelerating the conversion of acetaminophen to NAPQI. (correct answer)
  3. directly depletes hepatic glutathione stores, reducing the capacity to detoxify NAPQI.
  4. inhibits the renal transporters responsible for clearing acetaminophen metabolites from the body.
Explanation: Phenytoin, like carbamazepine, phenobarbital, and chronic alcohol, is a potent inducer of cytochrome P450 enzymes, including CYP2E1. Enzyme induction increases the metabolic capacity of the oxidative pathway, leading to a greater fraction of an acetaminophen dose being converted to the toxic metabolite NAPQI. This increases the risk of glutathione depletion and subsequent liver injury, even at doses that might be tolerated by a person not on an inducing agent. The other mechanisms described are less significant or incorrect.